Shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) fell 3.5% during mid-day trading on Wednesday . The company traded as low as $6.53 and last traded at $6.61, with a volume of 819,286 shares changing hands. The stock had previously closed at $6.85.

A number of research firms have recently issued reports on PGNX. Brean Capital restated a “buy” rating and issued a $14.00 target price on shares of Progenics Pharmaceuticals in a report on Friday, May 6th. Zacks Investment Research downgraded shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, May 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price target on shares of Progenics Pharmaceuticals in a research note on Friday, July 22nd. Jefferies Group reaffirmed a “buy” rating on shares of Progenics Pharmaceuticals in a research note on Friday, June 10th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $9.00 price target on shares of Progenics Pharmaceuticals in a research note on Wednesday, July 20th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $9.95.

The company has a 50-day moving average of $5.36 and a 200-day moving average of $4.83. The firm’s market cap is $467.50 million.

Progenics Pharmaceuticals (NASDAQ:PGNX) last released its earnings results on Thursday, August 4th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.05. The business had revenue of $8.50 million for the quarter, compared to analyst estimates of $6.33 million. During the same period in the prior year, the firm posted ($0.17) EPS. Progenics Pharmaceuticals’s revenue was up 337.6% on a year-over-year basis. On average, analysts anticipate that Progenics Pharmaceuticals Inc. will post $0.12 EPS for the current fiscal year.

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.